SOURCE: Barrier Therapeutics, Inc.

February 02, 2007 13:30 ET

Barrier Therapeutics to Present Scientific Posters at the American Academy of Dermatology 65th Annual Meeting

PRINCETON, NJ -- (MARKET WIRE) -- February 2, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that it will be displaying several key scientific poster presentations at the American Academy of Dermatology (AAD) 65th Annual Meeting being held in Washington, D.C. on February 2-6, 2007.

"We are proud to present clinical data at this year's AAD meeting on our most recently launched products, Xolegel and Vusion, as well as three candidates in development," said Geert Cauwenbergh, Ph.D., Chief Executive Officer and Founder of Barrier Therapeutics. "Our participation at this key meeting emphasizes Barrier Therapeutics' commitment to the field of therapeutic dermatology and to further advancing our growing commercial presence and innovative pipeline."

Members of Barrier Therapeutics' commercial and development teams will be in attendance discussing the results outlined in the poster presentations during this year's annual AAD meeting. To view these posters in their entirety, please visit the Press Release section of Barrier Therapeutics' website at http://www.barriertherapeutics.com.

The poster presentations are entitled:

Posters Related to Xolegel™

--  "Comparison of Ketoconazole USP Solubility in 2% Gel and 2% Cream
    Formulations"; Poster Number: P809
--  "Anti-Inflammatory Effects of Ketoconazole: Clinical Benefits In the
    Treatment of Seborrheic Dermatitis"; Poster Number: P807
    
Posters Related to Vusion™
--  "Comparative Absorption of 0.25% and 2% Miconazole Nitrate
    Preparations in Infants with Diaper Dermatitis"; Poster Number: P820
--  "Investigating the Role of Reactive Oxygen Species In the Mechanism of
    Action of Miconazole and Effects on the Treatment of Diaper Dermatitis";
    Poster Number: P808
--  "Involvement of Membrane Rafts in Antifungal Mode of Action of
    Miconazole"; Poster Number: P1818
    
Posters Related to Products in Development
--  "The Pharmacokinetic Profile, Safety and Tolerability of the New H1
    Antihistamine, Vapitadine (R129160), after Single and Multiple Oral Doses
    in Healthy Volunteers"; Poster Number: P818; current product candidate
    referred to as Hivenyl™
--  "Post-Treatment Levels of Pramiconazole, a New Oral Antifungal, in
    Nails"; Poster Number: 1505; current product candidate referred to as
    Azoline
--  "Tolerability, Safety and Pharmacokinetics of Single and Multiple
    Oral Dosages of R115866 in Healthy Volunteers"; Poster Number: P2782;
    current product candidate referred to as Rambazole™
    
Barrier Therapeutics' Booth (#2545) will be located in Hall C of the Washington, D.C. Convention Center.

More information on the American Academy of Dermatology Annual Meeting can be found at http://www.aad.org.

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including acne, psoriasis, onychomycosis and other fungal infections such as tinea versicolor. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion, Solagé, Hivenyl and Rambazole are trademarks of Barrier Therapeutics, Inc.

Safe Harbor Statement

In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Barrier's current expectations or forecasts of future events. Barrier's performance and financial results could differ materially from those reflected in these forward-looking statements due to the marketplace acceptance of Barrier's products, Barrier's ability to execute its commercial and clinical strategy, the decisions of regulatory authorities, the results of clinical trials and strategic decisions regarding its pipeline, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements, please see the risk factors in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 which is on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Barrier undertakes no obligation to update publicly any forward-looking statement.

In addition, please note that success in clinical trials does not mean that subsequent trials will confirm earlier findings. No assessment of the efficacy or safety of any product candidate can be considered definitive until all clinical trials needed to support a submission for marketing approval are complete.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Tracy J. Henrikson
    (609) 945-2610